Oramed to Present at Conferences Next Week

JERUSALEM, May 18, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that  Chief Executive Officer, Nadav Kidron, will present at three conferences next week in Tel Aviv, Israel.

Oppenheimer’s 17th Annual […]

Categories: Press Releases|Tags: |

Oramed Granted Canadian Patent for GLP-1 Analog Capsule

JERUSALEM, May 9, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent titled, “Methods and Compositions for Oral Administration of […]

Categories: Press Releases|Tags: |

Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule

JERUSALEM, May 2, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that based on positive preclinical data, the Company is developing a new drug candidate, a weight loss treatment […]

Categories: Press Releases|Tags: |

Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule

JERUSALEM, April 20, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has granted the Company a patent titled, “Methods and Compositions for Treating Diabetes: […]

Categories: Press Releases|Tags: |

Journal of Diabetes Science and Technology Publishes Scientific Paper Authored by Oramed Scientists

JERUSALEM, April 4, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today a new paper co-authored by Oramed’s Chief Scientific Officer, Dr. Miriam Kidron, and Dr. Ehud Arbit.  The paper, […]

Categories: Press Releases|Tags: |

Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017

JERUSALEM, March 22, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed’s Chief Scientific Officer, will deliver a presentation titled, “Oral Insulin for Diabetes Treatment: […]

Categories: Press Releases|Tags: |

Oramed Appoints Dr. Ronald Law as Chief Strategy Officer

JERUSALEM, March 21, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Ronald Law to the newly created position of Chief Strategy Officer.

“We are very pleased to welcome Dr. Law to Oramed as […]

Categories: Press Releases|Tags: |

Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences

JERUSALEM, Feb. 7, 2017  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place February 13-14, 2017 […]

Categories: Press Releases|Tags: |

Oramed’s ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study

Preparing to submit IND and commence U.S. FDA Phase IIb trial in 2017

JERUSALEM, Nov. 29, 2016  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it successfully concluded a Phase Ib study of ORMD-0901, the Company’s proprietary […]

Categories: Press Releases|Tags: |

Oramed Receives Additional $4 Million Milestone Payment From HTIT

Totaling $29.5 Million in payments from HTIT received to date

JERUSALEM, October 6, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received an additional milestone payment of $4 million from Hefei Tianhui Incubator of Technologies […]

Categories: Press Releases|Tags: |